Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
- Close
- COMPANY OVERVIEW
- MANAGEMENT
- BOARD OF DIRECTORS
AREAS OF FOCUS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
- STORIES
CONTACT US

Main Content

Slide

AKARI THERAPEUTICS IS AN INNOVATIVE TARGETED

ONCOLOGY COMPANY BUILT ON NEXT GENERATION

ANTIBODY-DRUG CONJUGATES (ADC)

CORPORATE PRESENTATION CORPORATE PRESENTATION

AND A NOVEL DISCOVERY ENGINE

RECENT PRESS RELEASES

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

July 29, 2025

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

July 23, 2025

Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 22, 2025

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its RecentlyGranted India Patent

June 25, 2025

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

June 18, 2025

Footer

Follow Us

Privacy Statement

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.